S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.35 (-0.31%)
AAPL   139.31 (+1.78%)
MSFT   226.10 (+0.50%)
FB   275.00 (+0.78%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.00 (-0.45%)
TSLA   846.22 (+0.15%)
NVDA   548.15 (-1.18%)
BABA   258.80 (-0.46%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.71 (+1.29%)
NIO   61.99 (+6.26%)
T   28.96 (+0.45%)
F   11.48 (-0.43%)
ACB   10.50 (-6.00%)
BA   206.02 (-0.67%)
DIS   172.75 (+0.86%)
NFLX   565.17 (-2.53%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.35 (-0.31%)
AAPL   139.31 (+1.78%)
MSFT   226.10 (+0.50%)
FB   275.00 (+0.78%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.00 (-0.45%)
TSLA   846.22 (+0.15%)
NVDA   548.15 (-1.18%)
BABA   258.80 (-0.46%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.71 (+1.29%)
NIO   61.99 (+6.26%)
T   28.96 (+0.45%)
F   11.48 (-0.43%)
ACB   10.50 (-6.00%)
BA   206.02 (-0.67%)
DIS   172.75 (+0.86%)
NFLX   565.17 (-2.53%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.35 (-0.31%)
AAPL   139.31 (+1.78%)
MSFT   226.10 (+0.50%)
FB   275.00 (+0.78%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.00 (-0.45%)
TSLA   846.22 (+0.15%)
NVDA   548.15 (-1.18%)
BABA   258.80 (-0.46%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.71 (+1.29%)
NIO   61.99 (+6.26%)
T   28.96 (+0.45%)
F   11.48 (-0.43%)
ACB   10.50 (-6.00%)
BA   206.02 (-0.67%)
DIS   172.75 (+0.86%)
NFLX   565.17 (-2.53%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.35 (-0.31%)
AAPL   139.31 (+1.78%)
MSFT   226.10 (+0.50%)
FB   275.00 (+0.78%)
GOOGL   1,892.56 (+0.45%)
AMZN   3,292.00 (-0.45%)
TSLA   846.22 (+0.15%)
NVDA   548.15 (-1.18%)
BABA   258.80 (-0.46%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.71 (+1.29%)
NIO   61.99 (+6.26%)
T   28.96 (+0.45%)
F   11.48 (-0.43%)
ACB   10.50 (-6.00%)
BA   206.02 (-0.67%)
DIS   172.75 (+0.86%)
NFLX   565.17 (-2.53%)
GILD   66.97 (-0.01%)
Log in
NASDAQ:FURX

(FURX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
(FURX) logo

MarketRank

Overall MarketRank

0.56 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
Current SymbolNASDAQ:FURX
CUSIP36106P10
WebN/A
Phone+1-919-4567800
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive FURX News and Ratings via Email

Sign-up to receive the latest news and ratings for FURX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











(FURX) (NASDAQ:FURX) Frequently Asked Questions

What stocks does MarketBeat like better than (FURX)?

Wall Street analysts have given (FURX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but (FURX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as (FURX)'s CEO?

1,448 employees have rated (FURX) CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among (FURX)'s employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of (FURX)'s key competitors?

What other stocks do shareholders of (FURX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (FURX) investors own include Pretium Resources (PVG), Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR), Baidu (BIDU), salesforce.com (CRM), Cisco Systems (CSCO), Gilead Sciences (GILD), Alphabet (GOOG), Incyte (INCY) and InvenSense (INVN).

What is (FURX)'s stock symbol?

(FURX) trades on the NASDAQ under the ticker symbol "FURX."

How can I contact (FURX)?

(FURX)'s mailing address is 3900 Paramount Pkwy Ste 150, MORRISVILLE, NC 27560-5401, United States. The healthcare company can be reached via phone at +1-919-4567800.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.